Ipsen: Dysport Approved For Use In Aesthetic Medicine In Canada – Quick Facts

By RTT News, April 09, 2013, 01:46:00 AM EDT

(RTTNews.com) - Ipsen (IPSEY.PK) said that it was granted a marketing authorization for Dysport by Health Canada for the temporary improvement in the appearance of moderate to severe frown lines in adult patients younger than 65 years of age. Medicis Aesthetics Canada, an unit of Valeant Pharmaceuticals, would market Dysport for use in aesthetic medicine in Canada. The launch may take place in April 2013.

The company said in a statement: "This presentation is in line with Ipsen's commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysport will now be available in Canada for the treatment of glabellar lines."

The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

More here:

Ipsen: Dysport Approved For Use In Aesthetic Medicine In Canada - Quick Facts